
Currently out of the existing stock ratings of Jack Lin, 3 are a BUY (75%), 1 are a HOLD (25%).
Analyst Jack Lin, currently employed at MORGAN STANLEY, has had 50% of price targets met with an average potential upside of 8.93%, reached in 29 days on average.
Jack Lin has documented 8 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HCM, HUTCHMED DRC at 22-Sep-2025.
Analyst best performing recommendations are on HCM (HUTCHMED DRC).
The best stock recommendation documented was for HCM (HUTCHMED DRC) on 5/14/2024. The price target of $17.5 was fulfilled within 37 days with a profit of $3.9 (18.22%), with a performance score of 4.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 10-Nov-2023
$14
$-0.9 (-6.04%)
$16
3 months 28 days ago
(23-Jul-2026)
6/9 (66.67%)
$3.04 (27.74%)
151
Buy Since 23-Oct-2019
$17
$2.1 (14.09%)
$27
4 months 13 days ago
(07-Jul-2026)
1/3 (33.33%)
$5.92 (53.43%)
85
Buy Since 10-Mar-2026
$20
$5.1 (34.23%)
$28
8 months 10 days ago
(10-Mar-2026)
0/2 (0%)
$6.11 (43.99%)
Hold Since 22-Sep-2025
$13.75
$17.5
1 years 1 months 29 days ago
(22-Sep-2025)
2/2 (100%)
$-2.91 (-17.47%)
58
Buy Since 12-Mar-2020
$50
$50
3 years 2 months 15 days ago
(05-Sep-2023)
1/6 (16.67%)
$35.15 (236.70%)
477
What Year was the first public recommendation made by Jack Lin?